clinical_trials
Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial
Confidence95·multiple reportsImportance97NP-EVT-20261108-48C9D01
Nature Medicine, Published online: 08 November 2026; doi:10.1038/s41591-026-04762-3 As presented at the 2026 American Heart Association Scientific Sessions, in a placebo-controlled randomized clinical trial, semaglutide significantly improved pulmonary artery wedge pressure and other hemodynamic parameters during low-intensity exercise in individuals with heart failure with preserved ejection fraction and obesity.
Read the original at the primary source
Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial
Rickey E. Carter · 11/8/2026, 12:00:00 AM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —